TORONTO--(BUSINESS WIRE)--Medworxx Solutions Inc. ("Medworxx") (TSX VENTURE: MWX) today announced a partnership with Leidos Health (formerly part of SAIC and includes the businesses of former maxIT Healthcare and Vitalize Consulting Solutions) which formalizes their agreement to leverage each organization’s global expertise in patient flow optimization. Leidos Health employs over 2,000 healthcare consultants globally and specializes in a variety of healthcare solutions.
Medworxx and Leidos Health began working together in 2012 on a province-wide implementation of the Medworxx Patient Flow Platform for Alberta Health Services (AHS). With 8000 licensed beds, AHS was the first provincial, fully integrated health system in Canada. The success of the AHS implementation, which is contributing to significant benefits and cost savings for AHS, prompted Medworxx and Leidos to continue to pursue opportunities to assist healthcare providers in the area of patient flow performance and analytics. The two organizations collaborated to research and present; “A provincial approach to how patient flow is reducing conservable days and saving costs in the province of Alberta”. The complete case study is available at: www.medworxx.com/Leidos-AHS.
“Our experience with Medworxx has been very positive – our collective strategy is to leverage Medworxx patient flow analytics and unique data review methodology and combine this with Leidos Health’s performance improvement capability. We have introduced a program where our Clinical Performance Team will use Medworxx software and tools as a key component of our patient flow review methodology,” said Steve Comber, President of Leidos Health.
“We are excited to be working with Leidos,” said Dan Matlow, President and CEO, Medworxx. “Leidos displayed insightful clinical expertise during the AHS implementation. We are confident the depth and scope of their Clinical Performance Team has the proven ability to support our patient flow roll outs internationally. We look forward to working with Leidos consultants around the world. ”
About Medworxx
Medworxx delivers health information
solutions to over 350 hospitals internationally; including Canada,
United States and United Kingdom. Medworxx helps hospitals meet patient
flow challenges, and requirements in compliance and education. Medworxx
Clinical Criteria – flagship of Medworxx Patient Flow that includes
electronic bed board and independent assessment components – currently
serves 35% of the acute care beds in Canada. Founded in 2004, Medworxx
is based in Toronto, ON, and publicly traded on the TSX Venture
Exchange: MWX.
For more information visit: http://www.medworxx.com.
About Leidos Health
Leidos Health is a wholly owned
subsidiary of Leidos [NYSE: LDOS], a national security, health and
engineering solutions company. Leidos Health is committed to providing
the highest quality clinical, business, and IT solutions for healthcare
enterprises across the U.S. and Canada. Its services include
implementation and optimizations of EHRs for all major vendors, as well
as enterprise solutions focused on high-level initiatives such as
Meaningful Use, ICD-10 transition, IT strategy, revenue cycle
management, accountable care transformation, risk management, technology
infrastructure, and project management. For more information, visit: www.LeidosHealth.com.
About Leidos
Leidos is a science and technology solutions
leader working to address some of the world’s toughest challenges in
national security, health, and engineering. The Company’s 23,000
employees support vital missions for our government and the commercial
sector, develop innovative solutions to drive better outcomes, and
defend our Nation’s digital and physical infrastructure from ‘new world’
threats. Leidos is headquartered in Reston, Va. and had approximately $6
billion in revenues for fiscal year 2013, on a pro forma basis,
following the spin-off of the company’s technical, engineering and
enterprise IT business on Sept. 27, 2013. For more information, visit: www.Leidos.com.
Disclaimer
The statements made in this press
release may contain forward-looking statements that may involve a number
of risks and uncertainties. Actual events or results could differ
materially from the company’s expectations and projections. The TSX
Venture Exchange has not reviewed this press release and neither
approved nor disapproved the information contained in this press release.
